ONO and Numab Forge Collaboration: Advancing Multi-specific Antibody NM49 through Option Agreement
Ono Pharmaceutical Co., Ltd. (Osaka, Japan), led by President and CEO Gyo Sagara, has announced a significant milestone today. The company has formalized an option and collaboration agreement with Numab…
Sarepta Therapeutics Receives U.S. FDA Acceptance for Efficacy Supplement Enabling Expansion of ELEVIDYS Indication
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, has announced today that the U.S. Food and Drug Administration (FDA) has accepted and filed the…
Grifols Reveals Encouraging Phase 3 Fibrinogen Clinical Trial Findings
In the AdFirst trial, Biotest’s fibrinogen concentrate (FC), BT524, successfully met the primary endpoint, demonstrating its efficacy in treating acquired fibrinogen deficiency (AFD) on par with standard care, while maintaining…
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
Today, GSK has announced the successful completion of its acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and…
GSK Finalizes Acquisition of Aiolos Bio
Today marks the completion of GSK’s acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company dedicated to addressing the unmet medical needs of patients with respiratory and inflammatory conditions. As…
Practical Two Day FDA Inspection Online Seminar – Research AndMarkets.com
ResearchAndMarkets.com is pleased to announce the addition of “FDA Inspection” training to its offerings. This two-day seminar is meticulously crafted to equip professionals in the pharmaceutical, biopharmaceutical, biologics, and medical…
Zoetis Reports Fourth Quarter and Full Year 2023 Results
Zoetis, a global leader in animal health, has announced its financial results for the fourth quarter and full year 2023, along with full-year guidance for 2024. In the fourth quarter…
European Commission Approves CASGEVY™ for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for…
FDA Grants Priority Review to Bristol Myers Squibb’s Augtyro™ (repotrectinib) Application for Treating Patients with NTRK-Positive Advanced Solid Tumors
Bristol Myers Squibb has disclosed that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro™ (repotrectinib) to treat adult and pediatric patients…
AbbVie Completes Acquisition of Immunogen
Today marks the completion of AbbVie’s acquisition of ImmunoGen (NASDAQ: IMGN), solidifying ImmunoGen’s integration into AbbVie’s portfolio. Robert A. Michael, AbbVie’s president and chief operating officer, expressed enthusiasm about the…
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States
Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA). This…
Give yourself credit for what you can achieve
The significance of maintaining health and well-being cannot be overstated, especially for individuals living with epilepsy, where the impacts of poor physical health, mental well-being, and overall quality of life…